The acquisition was originally expected to close in the first half of 2020. Mr. Neidorff, also chairman and president of Centene, told investors the health insurer has received required approval in eight states for the $17.3 billion deal, which is ahead of schedule. Centene filed for approval in 27 states.
Where applicable, Centene and WellCare have begun looking at divesting units that could raise antitrust concerns, Mr. Neidorff added. In June, the insurers said they received a request for additional information from the Department of Justice, which they expected given the size of the deal.
Centene saw double-digit growth in its revenue and profit during the second quarter of fiscal year 2019. Centene ended the quarter with a $495 million profit, up 65 percent from $300 million reported in the same period in 2018.
More articles on payers:
UnitedHealth records $3.3B profit in Q2
New York insurer opens office in hospital
The average price for treating primary care conditions in ED? $2,032, UnitedHealth says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
